The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

Edward Jones, a financial services firm, upgraded CVS Health (NYSE:CVS) stock from Hold to Buy. The upgrade comes as the stock, which InvestingPro analysis shows is currently undervalued, has posted a ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

Evercore ISI raised the firm’s price target on CVS Health (CVS) to $65 from $60 and keeps an Outperform rating on the shares. Given 2025 will ...

Edward Jones has upgraded CVS Health (CVS) to buy from hold, citing a potential turnaround in its Aetna insurance business. Read more here.

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their ...

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group ... bringing in more than $7.3 billion in “excess” revenue over six years, the Federal Trade Commission said in a report on ...

Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...